Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. announced that, as expected, each party has received a request for additional information (commonly referred to as a “second request”) from the US Federal Trade Commission (FTC) in connection with Teva's pending acquisition of Cephalon. The parties have been cooperating with the FTC staff since shortly after the announcement of the transaction and intend to continue to cooperate with the FTC to obtain HSR clearance as promptly as possible.

The effect of the second request is to extend the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) waiting period until thirty days after the parties have substantially complied with the request, unless that period is terminated sooner by the FTC. The companies continue to expect that the transaction will be completed in the third quarter of 2011, following completion of the HSR clearance process, the clearance by the European Commission under the EC Merger Regulation, as well as the approval of Cephalon stockholders.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.